Relationship Between Pretreatment Prognostic Factors, 11C-Acetate PET/CT, and 1H-MRS
| PSA velocity (ng/mL/y) | Clinical risk group | |||||
| Prognostic factor | <0.4 | 0.4–1.0 | >1.0 | 1 | 2 | 3 |
| SUV maximum | 5.6 ± 1.3 | 6.6 ± 3.2 | 5.6 ± 1.2 | 5.1 ± 1.1 | 6.4 ± 2.7 | 6.1 ± 1.1 |
| SUV 60% | 3.6 ± 0.8 | 3.9 ± 1.2 | 3.6 ± 0.7 | 3.3 ± 0.6 | 4.0 ± 1.0 | 3.9 ± 0.7 |
| CCP/C maximum | 1.52 ± 0.48 | 1.37 ± 0.10 | 1.72 ± 0.41 | 1.41 ± 0.32 | 1.77 ± 0.43 | 1.43 ± 0.37 |
| CCP/C average | 0.70 ± 0.09 | 0.76 ± 0.20 | 0.88 ± 0.27 | 0.73 ± 0.22 | 0.85 ± 0.22 | 0.78 ± 0.23 |